MedTrace Logo

Chinese Spondyloarthritis Inception Cohort (CESPIC)

NCT05960864 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-04-17

No results posted yet for this study

Summary

The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

Conditions

  • Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)
  • Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
  • Axial Psoriatic Arthritis (axPsA)
  • Acute Anterior Uveitis (AAU)
  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)
  • Reactive Arthritis (ReA)

Interventions

DRUG

Celecoxib

If we find any behavior that affects the safety of patients in the experiment, we will stop

Sponsors & Collaborators

  • Southwest Hospital, China

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2025-08-31
Completion
2030-08-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05960864 on ClinicalTrials.gov